Cordlife Group (CLIFF) 0.8800 $CLIFF
Global Market Study on UCB Banking 2015: Asia-Pacific to Witness Highest Growth by 2020
M2 - Wed Jul 08, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c7m2q2/global_market) has announced the addition of the "Global Market Study on UCB Banking: Asia-Pacific to Witness Highest Growth by 2020" report to their offering. The global UCB banking market was valued at 10,900 million in 2010 and it expanded to USD 12,774.8 million in 2013. North America has the largest market share, followed by Europe and Asia-Pacific, in the global UCB banking market. Globally, increasing prevalence of chronic diseases coupled with the emerging field of regenerative medicines is driving the UCB banking market. In addition, various government associations and initiatives are also supporting in the growth of the UCB banking market. North America has the largest market for UCB banking. The U.S., followed by Canada, is the largest market for UCB banking in the region. Increasing prevalence of chronic diseases is the key driver of the UCB banking market. In addition, initiatives by various government associations have also led to the increase in awareness about the importance of cord blood donation in the region. In Europe, the UCB banking market is growing due to increased awareness about potential applications of cord blood in the treatment of life-threatening diseases. In addition, increasing number of live births is also playing a vital role in the growth of UCB banking market in Europe. For instance, according to Eurostat, in 2010, 807,271 live births registered in 2010 and the number reached to 812,970 by 2013 in the U.K.. Due to increased awareness about potential of cord blood, newborns family donates and preserves cord blood either in private or public banks in Europe. However, Asia-Pacific is the fastest growing region in the UCB banking market. This is due to increasing prevalence of chronic diseases in the region. In addition, raising awareness about potential applications of cord blood and increasing number of live births are also contributing in the growth of UCB banking market in the region. China has the highest number of live births, followed by India around the world. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Therapeutic Application of UCB Chapter 7 Market Size and Forecast by Storage Option Chapter 8 Market Size and Forecast by Geography Chapter 9 Competitive Scenario Chapter 10 Company Profiles - China Cord Blood Corporation - Cord Blood America, Inc. - Cord Blood Registry Systems, Inc. - Cordlife Group Limited - Cryo-Cell International, Inc. - Esperite N.V. - NeoStem, Inc. - Smart Cells International, Ltd. - StemCyte - ViaCord For more information visit http://www.researchandmarkets.com/research/c7...bal_market
NBS: 2.25 (-0.09), CO: 5.29 (+0.04)
Golden Meditech Proposes to Purchase CCBC Convertible Notes Held by Magnum and CCBC Convertible Notes and CCBC Shares Held by CGL
PR Newswire - Fri May 08, 8:05AM CDT
Golden Meditech Holdings Limited ("Golden Meditech", or the "Company", together with its subsidiaries collectively as the "Group", 801.HK; 910801.TW), a leading integrated healthcare enterprise in China announced today that it has entered into an agreement (the "Magnum Agreement"
with Magnum Opus International Holdings Limited ("Magnum" to purchase the 7% senior convertible notes due 2017 with an aggregate outstanding principal amount of US$25 million (equivalent to approximately HK$194 million) (the "Magnum Note" issued by China Cord Blood Corporation ("CCBC" , a non-wholly owned subsidiary of the Group. Golden Meditech also entered into an agreement (the "CGL Agreement" with Cordlife Group Limited ("CGL" to purchase the 7% senior convertible notes due 2017 with an aggregate outstanding principal amount of US$25 million (equivalent to approximately HK$194 million) (the "CGL Note" issued by CCBC and 9.13% of the issued share capital of CCBC (the "CGL Sale Shares" .
Global Market Study on UCB Banking 2015: Asia-Pacific to Witness Highest Growth by 2020
M2 - Wed Jul 08, 4:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c7m2q2/global_market) has announced the addition of the "Global Market Study on UCB Banking: Asia-Pacific to Witness Highest Growth by 2020" report to their offering. The global UCB banking market was valued at 10,900 million in 2010 and it expanded to USD 12,774.8 million in 2013. North America has the largest market share, followed by Europe and Asia-Pacific, in the global UCB banking market. Globally, increasing prevalence of chronic diseases coupled with the emerging field of regenerative medicines is driving the UCB banking market. In addition, various government associations and initiatives are also supporting in the growth of the UCB banking market. North America has the largest market for UCB banking. The U.S., followed by Canada, is the largest market for UCB banking in the region. Increasing prevalence of chronic diseases is the key driver of the UCB banking market. In addition, initiatives by various government associations have also led to the increase in awareness about the importance of cord blood donation in the region. In Europe, the UCB banking market is growing due to increased awareness about potential applications of cord blood in the treatment of life-threatening diseases. In addition, increasing number of live births is also playing a vital role in the growth of UCB banking market in Europe. For instance, according to Eurostat, in 2010, 807,271 live births registered in 2010 and the number reached to 812,970 by 2013 in the U.K.. Due to increased awareness about potential of cord blood, newborns family donates and preserves cord blood either in private or public banks in Europe. However, Asia-Pacific is the fastest growing region in the UCB banking market. This is due to increasing prevalence of chronic diseases in the region. In addition, raising awareness about potential applications of cord blood and increasing number of live births are also contributing in the growth of UCB banking market in the region. China has the highest number of live births, followed by India around the world. Key Topics Covered: Chapter 1 Preface Chapter 2 Market Synopsis Chapter 3 Porter's Five Forces Analysis Chapter 4 Industry overview Chapter 5 Global Market Size and Forecast Chapter 6 Market Size and Forecast by Therapeutic Application of UCB Chapter 7 Market Size and Forecast by Storage Option Chapter 8 Market Size and Forecast by Geography Chapter 9 Competitive Scenario Chapter 10 Company Profiles - China Cord Blood Corporation - Cord Blood America, Inc. - Cord Blood Registry Systems, Inc. - Cordlife Group Limited - Cryo-Cell International, Inc. - Esperite N.V. - NeoStem, Inc. - Smart Cells International, Ltd. - StemCyte - ViaCord For more information visit http://www.researchandmarkets.com/research/c7...bal_market
NBS: 2.25 (-0.09), CO: 5.29 (+0.04)
Golden Meditech Proposes to Purchase CCBC Convertible Notes Held by Magnum and CCBC Convertible Notes and CCBC Shares Held by CGL
PR Newswire - Fri May 08, 8:05AM CDT
Golden Meditech Holdings Limited ("Golden Meditech", or the "Company", together with its subsidiaries collectively as the "Group", 801.HK; 910801.TW), a leading integrated healthcare enterprise in China announced today that it has entered into an agreement (the "Magnum Agreement"
with Magnum Opus International Holdings Limited ("Magnum" to purchase the 7% senior convertible notes due 2017 with an aggregate outstanding principal amount of US$25 million (equivalent to approximately HK$194 million) (the "Magnum Note" issued by China Cord Blood Corporation ("CCBC" , a non-wholly owned subsidiary of the Group. Golden Meditech also entered into an agreement (the "CGL Agreement" with Cordlife Group Limited ("CGL" to purchase the 7% senior convertible notes due 2017 with an aggregate outstanding principal amount of US$25 million (equivalent to approximately HK$194 million) (the "CGL Note" issued by CCBC and 9.13% of the issued share capital of CCBC (the "CGL Sale Shares" . 
